drugset / Trial / NCT03606837
68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Intermediate Risk Prostate Cancer Imaging
NaSingle-groupOpen-labelTreatment
Summary
Patients with primary intermediate risk prostate cancer for whom radical prostatectomy is indicated, will be invited to participate to the present study. Positron Emission Tomography coupled with scanner (PET-CT) using a radiotracer : 68Ga-RM2 and Positron Emission Tomography coupled with scanner (PET-CT) using another radiotracer : 68Ga-PSMA-617, will be scheduled.
Timeline
- Start
- 2019-07-11
- Primary completion
- 2023-06-15
- Completion
- 2023-07-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-RM2 | Diagnostic / imaging agent | — | — |
| Subject | VIPIVOTIDE TETRAXETAN GALLIUM | Diagnostic / imaging agent | — | — |